Iovance Biotherapeutics (NASDAQ:IOVA) reaffirmed FY2026 revenue guidance of $350–$370M and Q2 $86–$88M while reporting ~$319M cash, expanding to 90+ treatment centers and 1,500+ patients as Amtagvi shows durable efficacy in melanoma and the company advances into more solid tumors and next‑gen cell therapies.
Previous Week Recap
- Iovance Revenue Guidance, Cash, Centers: Iovance (IOVA) reiterated FY2026 revenue guidance $350–$370M, Q2 $86–$88M; reported ~$319M cash (Mar 31, 2026), >90 treatment centers and 1,500+ patients treated.
- Amtagvi Durable Efficacy In Melanoma: Iovance Biotherapeutics (IOVA): Amtagvi showed durable efficacy in advanced melanoma. Company advancing pipeline into additional solid tumors and next‑generation cell therapy programs.
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original sources.